Company Analysis
Sign in

Unicycive Therapeutics, Inc. (UNCY)

Nasdaq: UNCY · Pharmaceutical Preparations · Los Altos, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade4.4
◀ Past 3.4● Present 3.7▶ Future 5.8
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 30, 2026Mar 31, 2025Mar 28, 2024Mar 31, 2023Mar 31, 2022·
Revenue··675951··
Research and development9,12120,01412,90212,4366,0801,015
Selling, general and administrative···38324558
General and administrative20,39612,1038,5476,5672,8971,005
Total operating expenses29,51732,11721,44919,0038,9772,020
Operating income-29,517-32,117-20,774-18,052-8,977-2,020
Interest expense7171826628244
Interest and investment income1,0121,261615···
Other income (expense), net··-9,770-6··
Total non-operating income (expense)2,962-4,612-9,770-6-1,040-244
Net income including non-controlling interests····-10,017-2,264
Net income-26,555-36,729-30,544-18,058-10,017-2,264
Net income to common shareholders-26,555-37,824-31,411-18,058-10,017·
Earnings per share, basic-1.67-5.65r-12.80b-12.00b-8.60b-2.70b
Earnings per share, diluted-1.67-5.65r-12.80b-12.00b-8.60b·
Weighted average shares, basic15,886,8766,698,513r2,453,931b1,505,705b1,167,575b849,969b
Weighted average shares, diluted15,886,8766,698,513r2,453,931b1,505,705b1,167,575b·
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-10 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:Revenues
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton UNCY · research, not advice